Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azilsartan + amlodipine tablets in primary hypertension uncontrolled on monotherapy
CTR20231206Phase 3Completed
- Sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azilsartan medoxomil + amlodipine in essential hypertension (3 arms), sponsored by Shanghai Huilun Pharmaceutical Co., Ltd. Primary endpoint: Change in trough seated diastolic blood pressure at week 8. Started Apr 2023; status: completed.
02
Drugs
azilsartan medoxomil + amlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20231206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231206.